Your session is about to expire
← Back to Search
Carfilzomib + Lenalidomide + Dexamethasone for Multiple Myeloma
Study Summary
This trial is testing carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone as a maintenance treatment for multiple myeloma after stem-cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 126 Patients • NCT03029234Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have moderate to severe numbness, tingling, or pain in my hands or feet.I have started or received treatment after a transplant.I cannot tolerate lenalidomide, carfilzomib, or dexamethasone.I have Waldenström's macroglobulinemia or IgM myeloma.Your heart's electrical activity (QT interval) is longer than normal on a screening heart test.I have mild to no diarrhea without taking medication for it.Your white blood cell count, red blood cell count, and platelet count are within certain healthy ranges.I haven't had a heart attack in the last 6 months and don't have severe heart issues.My blood pressure or diabetes is not well-managed.I have not taken antibiotics, antivirals, or antifungals for an infection in the last two weeks.I haven't had cancer except for certain types in the last 3 years.I have been under cancer treatment for over a year.I will provide a bone marrow sample for the study.My cancer has spread to my brain or spinal cord.I agree to use protection during sex throughout the study and for 28 days after, even though I've had a vasectomy.I had a stem cell transplant for my condition and my disease hasn’t worsened in the first 100 days post-transplant.I started my first cancer treatment less than a year ago and have tried up to 2 different treatments.My liver tests are within normal limits.I have had no more than two initial treatments, not counting dexamethasone alone.I have not had radiotherapy in the last 14 days, or within 7 days if it was to a single area.I have been diagnosed with plasma cell leukemia.My condition worsened after my first treatment.I am fully active or can carry out light work.Your disease is getting worse according to specific guidelines.I have not had major surgery in the last 3 weeks.I have had a blood clot in my veins or lungs.I am 18 years old or older.I have POEMS syndrome.My kidney function, measured by creatinine clearance, is sufficient.I changed my treatment due to poor response or side effects but my cancer has not worsened.I do not have an active HIV, HBV (unless from vaccine), or HCV infection.
- Group 1: Lenalidomide (Control)
- Group 2: Experimental Combination Regimen
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other examples of Carfilzomib being used in research?
"Carfilzomib was first studied in 2002 and there have been 1376 completed trials as of now. There are 736 active trials being conducted globally, with a large number centred around Detroit, Michigan."
What are the Carfilzomib's common usages?
"Carfilzomib is a medication typically used to treat ophthalmia, sympathetic. It can also be effective in managing branch retinal vein occlusion and macular edema among patients that have undergone at least two different rounds of systemic chemotherapy."
Are individuals currently being sought for this experiment?
"The study in question is not enrolling patients at the moment, according to the information on clinicaltrials.gov. This research was originally posted on April 26th, 2016 but has since been edited on June 29th, 2021. Although this specific trial isn't looking for candidates currently, there are 1562 other trials that are actively recruiting right now."
When was Carfilzomib cleared by the FDA?
"There is some efficacy data and multiple safety trials for Carfilzomib, giving it a score of 3 on our Power team's scale."
What is the total amount of people that can partake in this research?
"This study is now closed to new patients. The clinical trial was posted on 4/26/2016 and edited for the last time on 6/29/2021. There are, however, 826 other trials for multiple myeloma and 736 studies involving Carfilzomib that are still recruiting participants."
Share this study with friends
Copy Link
Messenger